Literature DB >> 16679465

Parkinson's disease and primate research: past, present, and future.

E A C Pereira1, T Z Aziz.   

Abstract

Scientific research involving non-human primates has contributed towards many advances in medicine and surgery. This review discusses its role in the progress made towards our understanding of Parkinson's disease and its treatment. Established medical treatments like dopamine agonists continue to need primate models to assess their efficacy, safety, and mechanism of action. The recently developed treatment of deep brain stimulation of the subthalamic nucleus required validation in primates before entering the clinic. Controversies surrounding future treatments such as gene therapy show the need for properly evaluated preclinical research using appropriate animal models before progression to clinical trials. Research on primates has played--and continues to play--a crucial part in deepening our understanding of Parkinson's disease, improving current therapies, and developing new treatments that are both safe and effective. In animal research, the "three Rs" of humane technique--reduction, refinement, and replacement--should be adhered to.

Entities:  

Mesh:

Year:  2006        PMID: 16679465      PMCID: PMC2563784          DOI: 10.1136/pgmj.2005.041194

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  50 in total

1.  Animal research: the need for a middle ground.

Authors:  R Smith
Journal:  BMJ       Date:  2001-02-03

Review 2.  Neural transplantation for the treatment of Parkinson's disease.

Authors:  Anders Björklund; Stephen B Dunnett; Patrik Brundin; A Jon Stoessl; Curt R Freed; Robert E Breeze; Marc Levivier; Marc Peschanski; Lorenz Studer; Roger Barker
Journal:  Lancet Neurol       Date:  2003-07       Impact factor: 44.182

3.  3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.

Authors:  A CARLSSON; M LINDQVIST; T MAGNUSSON
Journal:  Nature       Date:  1957-11-30       Impact factor: 49.962

Review 4.  Where is the evidence that animal research benefits humans?

Authors:  Pandora Pound; Shah Ebrahim; Peter Sandercock; Michael B Bracken; Ian Roberts
Journal:  BMJ       Date:  2004-02-28

5.  Surveying the literature from animal experiments.

Authors:  Roger Lemon; Stephen B Dunnett
Journal:  BMJ       Date:  2005-04-30

6.  Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease.

Authors:  L V Laitinen; A T Bergenheim; M I Hariz
Journal:  J Neurosurg       Date:  1992-01       Impact factor: 5.115

7.  Decerebrate Rigidity, and Reflex Coordination of Movements.

Authors:  C S Sherrington
Journal:  J Physiol       Date:  1898-02-17       Impact factor: 5.182

Review 8.  Investigating levodopa-induced dyskinesias in the parkinsonian primate.

Authors:  J W Langston; M Quik; G Petzinger; M Jakowec; D A Di Monte
Journal:  Ann Neurol       Date:  2000-04       Impact factor: 10.422

9.  Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey.

Authors:  Ned Jenkinson; Dipankar Nandi; R Chris Miall; John F Stein; Tipu Z Aziz
Journal:  Neuroreport       Date:  2004-12-03       Impact factor: 1.837

10.  Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver, by S. A. Kinnier Wilson, (From the National Hospital, and the Laboratory of the National Hospital, Queen Square, London) Brain 1912: 34; 295-509.

Authors:  Alastair Compston
Journal:  Brain       Date:  2009-08       Impact factor: 13.501

View more
  2 in total

Review 1.  Pedunculopontine stimulation from primate to patient.

Authors:  Erlick A C Pereira; Dipankar Nandi; Ned Jenkinson; John F Stein; Alexander L Green; Tipu Z Aziz
Journal:  J Neural Transm (Vienna)       Date:  2011-03-30       Impact factor: 3.575

2.  Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes.

Authors:  Lei Xia; Dianxuan Guo; Bing Chen
Journal:  Exp Ther Med       Date:  2017-09-29       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.